专题报告
6月3日 1:00 PM - 2:15 PM
地点：S100a
扩展教育专场：脑转移的多学科管理
Use of Stereotactic Radiosurgery in Treating Brain Metastases: Is There a Role for Whole-Brain Radiation Therapy?
立体定向放射外科治疗脑转移：全脑放射治疗还有应用空间吗？
Paul D. Brown， MD
The University of Texas MD Anderson Cancer Center
Imaging and Clinical Endpoints in Brain Metastases Trials
脑转移试验中的影像学和临床研究终点
Riccardo Soffietti， MD
University and San Giovanni Battista Hospital
Targeted Therapy in Brain Metastases: Ready for Prime Time?
脑转移靶向治疗的黄金时代是否来临?
Manmeet Singh Ahluwalia， MD - Chair
Cleveland Clinic
6月4日4:45 PM - 6:00 PM
地点：Hall D2
Gianni Bonadonna奖颁奖仪式及获奖演说
雌激素受体和生长因子受体间的交联：内分泌治疗耐药的启示和新的对抗策略
Crosstalk Between Estrogen and Growth Factor Receptor Pathways: Implications for Endocrine Therapy Resistance and New Strategies to Overcome It
C. Kent Osborne， MD
Baylor College of Medicine
6月6日8:00 AM - 9:15 AM
地点：S100a
教育专场-乳腺癌康复者：最佳管理策略
通过调整生活方式降低风险
Risk Reduction Through Lifestyle Modifications
Michelle E. Melisko， MD
UCSF Helen Diller Family Comprehensive Cancer Center
通过系统管理提高依从性
Improving Adherence Through Symptom Management
Debra L. Barton， PhD， AOCN， RN
University of Michigan
6月6日8:00 AM - 9:15 AM
地点：S404
教育专场-改善乳腺癌的风险评估：额外的基因、额外的筛查
扩大乳腺癌患者的生殖细胞系筛查
Extending Germline Testing in Patients with Breast Cancer.
Allison W. Kurian， MD， MSc
Stanford University School of Medicine
风险细化和分层筛查方法
Risk Refinement and Stratify Screening Approaches
Susan M. Domchek， MD - Speaker
University of Pennsylvania Perelman School of Medicine
6月6日11:30 AM - 12:45 PM
地点：Hall D1
教育专场-HER-2阳性乳腺的进展和争议
HER-2阳性乳腺癌的耐药机制
Mechanisms of Resistance in HER2+ Breast Cancer
Kimberly L. Blackwell， MD
Duke University Medical Center
HER-2阳性乳腺癌的新治疗选择
Emerging Therapeutic Options for HER2+ Breast Cancer
Miguel Martin， MD， PhD
Hospital General Universitario Gregorio Maraon
6月6日3:00 PM - 4:15 PM
地点：S100bc
教育专场-ASCO /北美放射学会联合会议：乳腺癌影像学
乳腺成像新技术和新方法
New Technologies and Techniques in Breast Imaging
Elizabeth Ann Morris， MD - Speaker
Memorial Sloan Kettering Cancer Center
6月6日4:45 PM - 6:00 PM
地点：Hall D1
教育专场：激素受体阳性乳腺癌的靶向治疗
（激素受体阳性）乳腺癌除激素治疗外，谁需要靶向药物？
Beyond Hormone Therapy for Breast Cancer: Who Needs Targeted Agents?
Hope S. Rugo
University of California， San Francisco
激素受体阳性乳腺癌靶向治疗的毒性管理
Managing Toxicity of Targeted Therapies for Hormone Receptor-Positive Breast Cancer
DejanJuric， MD
Massachusetts General Hospital Cancer Center
6月7日8:00 AM - 9:15 AM
地点：S406
教育专场-三阴性乳腺癌的改变即将来临吗？
铂类治疗三阴性乳腺癌的最佳应用
Optimal Use of Platinum Chemotherapy in Triple-Negative Breast Cancer
Rebecca Alexandra Dent， MD
National Cancer Center Singapore
免疫治疗和免疫共轭物治疗三阴性乳腺癌：前景和潜力
Immunotherapy and Immunoconjugates for Triple-Negative Breast Cancer: Promise and Potential
Vandana Gupta Abramson， MD
Vanderbilt University Medical Center
6月7日9:45 AM - 11:00 AM
地点：S406
教育专场-激素敏感的绝经前乳腺癌的治疗
乳腺癌诊断后年轻妇女的卵巢保护和妊娠争议
Controversies in Fertility Preservation for Young Women and Pregnancy After Breast Cancer Diagnosis.
Hatem A. Azim， MD， PhD
Institut Jules Bordet
年轻女性激素治疗的毒性管理
Managing Hormone Therapy Toxicity in Young Women
Hatem A. Azim， MD， PhD
Institut Jules Bordet
6月7日11:30 AM - 12:45 PM
地点：S406
教育专场-少就是多：治疗选择的多学科讨论
局部治疗中的争议：手术和放疗
Controversies in Local Therapy: Surgery and Radiation
Laura Esserman， MD， MBA
University of California， San Francisco
导管原位癌的治疗争议：多少才够？
Controversies in the Treatment of Ductal Carcinoma In Situ: How Much Is Enough?
Eun-Sil Shelley Hwang， MD
Duke University
重点发布研究
6月5日1:40 PM - 1:55 PM
地点：Hall B1
全体大会报告
Abstract LBA1
A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.
6月3日4:30 PM - 6:00 PM
地点：Hall D 1
临床科学研讨会：乳腺癌治疗的未来方向：新药、新标志物
Abstract 510
MONARCH1: Results from a phase II study of abemaciclib， a CDK4 and CDK6 inhibitor， as monotherapy， in patients with HR+/HER2- breast cancer， after chemotherapy for advanced disease.
4:42 PM - 4:54 PM
Abstract 511
Prognostic and predictive value of circulating ESR1 mutations in metastatic breast cancer patients (mBC) progressing under aromatase inhibitor (AI) treatment.
5:06 PM - 5:18 PM
6月4日1:15 PM - 4:15 PM
地点：HAll D2
口头报告：三阴性/细胞毒性/局部治疗
化疗
Abstract 1000
Interim joint analysis of the ABC (anthracyclines in early breast cancer) phase III trials (USOR 06-090， NSABP B-46I/USOR 07132， NSABP B-49 [NRG Oncology]) comparing docetaxel + cyclophosphamide (TC) v anthracycline/taxane-based chemotherapy regimens (TaxAC) in women with high-risk， HER2-negative breast cancer.
Abstract 1001
Adjuvant capecitabine in combination with docetaxel (T)， epirubicin (E)， and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial.
Abstract 1002
PANTHER: Prospective randomized phase III trial of tailored and dose-dense versus standard tri-weekly adjuvant chemotherapy for high-risk breast cancer in the modern era of endocrine and anti-HER2 therapy.
Abstract 1004 （徐兵河教授口头报告）
Randomized phase III trial of utidelone， a genetically engineered epothilone analog， in combination with capecitabine versus capecitabine alone for metastatic breast cancer patients with previous taxane and anthracycline treatment.
手术治疗
Abstract 1005
A randomized controlled trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer: Turkish Study (Protocol MF07-01).
Abstract 1006
A prospective analysis of surgery and survival in stage IV breast cancer (TBCRC 013).
Abstract 1007
Ten-year survival results of ACOSOG Z0011: A randomized trial of axillary node dissection in women with clinical T1-2 N0 M0 breast cancer who have a positive sentinel node (Alliance).
免疫治疗
Abstract 1003
Randomized phase II/III trial of active immunotherapy with OPT-822/OPT-821 in patients with metastatic breast cancer.
6月6日1:15 PM - 4:15 PM
地点：Hall D1
口头报告（HER-2/ER）
HER-2靶向治疗
Abstract 501
Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: 5-year outcomes of NSABP protocol B-41.
1:27 PM - 1:39 PM
Abstract LBA503
Heritage: A phase III safety and efficacy trial of the proposed trastuzumabbiosimilar Myl-1401O versus Herceptin.
2:15 PM - 2:27 PM
内分泌治疗
Abstract 505
Predictors of recurrence during years 5-14 in 46，138 women with ER+ breast cancer allocated 5 years only of endocrine therapy (ET).
Abstract LBA506
Patient-reported outcomes from MA.17R: A randomized trial of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.
Abstract 507
PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2- advanced breast cancer (ABC).
3:27 PM - 3:39 PM
京公网安备 11010502033352号